Swiss National Bank Sells 600 Shares of Amedisys, Inc. (NASDAQ:AMED)

Swiss National Bank trimmed its stake in Amedisys, Inc. (NASDAQ:AMED) by 0.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,800 shares of the health services provider’s stock after selling 600 shares during the quarter. Swiss National Bank owned 0.19% of Amedisys worth $6,157,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in shares of Amedisys by 413.4% in the 3rd quarter. SG Americas Securities LLC now owns 196,713 shares of the health services provider’s stock worth $18,985,000 after purchasing an additional 158,398 shares during the last quarter. Highbridge Capital Management LLC increased its stake in Amedisys by 34.7% during the 2nd quarter. Highbridge Capital Management LLC now owns 323,200 shares of the health services provider’s stock valued at $29,670,000 after purchasing an additional 83,200 shares in the last quarter. Murchinson Ltd. increased its stake in Amedisys by 69.2% during the 2nd quarter. Murchinson Ltd. now owns 123,979 shares of the health services provider’s stock valued at $11,381,000 after purchasing an additional 50,716 shares in the last quarter. Calamos Advisors LLC raised its holdings in Amedisys by 11.6% in the second quarter. Calamos Advisors LLC now owns 397,347 shares of the health services provider’s stock worth $36,476,000 after buying an additional 41,220 shares during the last quarter. Finally, Canada Pension Plan Investment Board lifted its stake in shares of Amedisys by 61.0% in the second quarter. Canada Pension Plan Investment Board now owns 79,200 shares of the health services provider’s stock worth $7,271,000 after buying an additional 30,000 shares in the last quarter. 94.36% of the stock is owned by institutional investors.

Amedisys Price Performance

Shares of AMED opened at $91.02 on Wednesday. Amedisys, Inc. has a twelve month low of $88.81 and a twelve month high of $98.95. The company has a market capitalization of $2.98 billion, a P/E ratio of 36.12, a price-to-earnings-growth ratio of 1.90 and a beta of 0.78. The firm has a 50 day moving average of $95.22 and a 200 day moving average of $95.74. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The business had revenue of $587.67 million during the quarter, compared to the consensus estimate of $586.75 million. During the same period in the previous year, the business posted $0.98 EPS. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.55 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.